Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.57 |
| ▸ | PGR | P06401 | 3/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12086345 | 0.84 | NR3C2 (0.55) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL16508906 | 0.81 | NR3C2 (0.52) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL8354304 | 0.77 | KMT2A (0.57) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL12000924 | 0.76 | KMT2A (0.56) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL7621989 | 0.76 | KMT2A (0.56) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL12922883 | 0.71 | KMT2A (0.46) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL5020955 | 0.70 | KMT2A (0.49) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL14102435 | 0.70 | NR3C1 (0.48) | NR3C1PGRNR3C2KMT2AALDH1A1 | |
| SCHEMBL7012078 | 0.69 | ITGB3 (0.47) | NR3C1NR3C2KMT2AALDH1A1TSHR | |
| SCHEMBL94732 | 0.69 | ALDH1A1 (0.68) | KMT2AALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | NR3C1 4865/4885PGR 1947/4885NR3C2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.